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tryptamine	 (5‐HT)),	 a	 neurotransmitter	 in	 the	 gut	 has	many	 effects	
which	are	relevant	to	this	aspect	of	IBS,	stimulating	intestinal	secre‐



























to	alosetron	was	 shown	 in	one	 trial	 to	be	greater	with	 the	homo‐
zygous	 l/l	 variant	 of	 the	 5‐HTTLPR	 (serotonin‐transporter‐linked	
polymorphic	 region)	 of	SLC6A4.7	 Furthermore,	 the	 gene	TPH1 en‐
coding	tryptophan	hydroxylase	1,	the	rate	limiting	enzyme	for	sero‐
tonin	synthesis	in	enterochromaffin	cells	of	the	gut,	contains	several	
single	 nucleotide	 polymorphisms	 (SNPs),	 including	 rs4537731	 and	
rs211105,	which	have	been	 reported	 to	predict	 responsiveness	 to	





















as	 IBS‐D	patients,	 underwent	 rectal	mucosal	 biopsy	 and	provided	
normal	values	for	colonic	transit	studies.
2.2 | Data collection
The	 following	 personal	 baseline	 data	 were	 collected:	 age,	 sex,	
Hospital	 Anxiety	 and	 Depression	 Scale	 (HADS)12	 score,	 Patient	
Health	Questionnaire	 12	 Somatic	 Symptom	 (PHQ‐12)13	 score	 and	
Perceived	Stress	Scale14	score.	 IBS	Quality	of	Life	Questionnaire15 
and	 IBS	 Severity	 Scoring	 System16	 scores	were	 collected	 at	 base‐
line	and	at	the	end	of	each	treatment	period.	A	previously	described	
daily	stool	diary17	was	used	to	collect	stool	form	information	(using	
the	Bristol	 Stool	 Form	Score	 (BSFS),18	 abdominal	 pain	 perception,	
urgency	 to	defecate	and	abdominal	bloating	 (all	 three	scored	on	a	
0‐3	scale).	Frequency	of	defecation	and	number	of	days	with	bloat‐





unprepared	 flexible	 sigmoidoscopy	 to	 obtain	 high	 rectal/sigmoid	
biopsies	and	57	consented	to	this	additional	procedure.	Two	of	the	
samples	were	 immediately	 frozen	 in	 liquid	 nitrogen	 for	 analysis	 of	
serotonin	and	5‐HIAA	content	by	high‐performance	 liquid	chroma‐
tography	(HPLC),	two	in	RNALater	for	gene	expression	studies,	one	
for	 incubation	at	25°C	 in	95%	O2	 for	assay	of	5‐HT	release	from	a	
0‐30	minute	period	as	previously	described20	(Data	S1).	Finally,	one	
biopsy	was	 embedded	 in	 paraffin	 for	 routine	 histology	 to	 exclude	
microscopic	 colitis.	Real‐time	polymerase	 chain	 reaction	 (PCR)	was	
used	 to	assess	 the	 relative	expression	of	TPH1	with	 respect	 to	 the	




We	 assessed	 fasting	 plasma	 5‐HIAA	 using	 HPLC	 as	 previously	
described.22
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2.5 | Genotyping
Blood	samples	were	taken	at	visit	1.	DNA	was	extracted	from	200	µl	
of	 citrated	 blood	 using	 the	QIAamp	DNA	Blood	Mini	 Kit	 (Qiagen	
Cat.	No.	51106)	and	subsequently	genotyped	 for	62	patients	who	
provided	 samples	 for	 the	 following	 polymorphisms:	 5‐HTTLPR	
(serotonin‐transporter‐linked	 polymorphic	 region)	 residing	 within	





(rs6766410)	 and	HTR3E	 c.*76G	 >	 A	 (rs56109847)	was	 carried	 out	














a	much	 lower	 placebo	 response	 rate.	 Therefore,	 in	 this	 paper,	we	
used	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 definition	 of	 a	

















baseline	 clinical	 features,	 biopsy	 results,	 final	 ondansetron	 dose,	












no	 differences	 between	 patients	 consented	 for	 biopsy	 and	 those	
TA B L E  1  Demographics	of	study	participants	showing	details	of	patients’	and	healthy	volunteers’	mental	health	and	bowel	function.	
There	were	no	significant	differences	between	those	undergoing	biopsy	and	those	choosing	not	to	have	this	extra	test
Variable
Patients without biopsy 
(n = 68)
Patients with biopsy 
(n = 57)
Heathy volunteers 
(n = 21) P value
Age 40	(12) 42	(12) 43	(18) .5921
Sex	(women),	n	(%) 53	(78) 36	(63) 16	(76) .1693
Patient	Health	Questionnaire	12 8	(3.5) 7.3	(3.7) 2.2	(1.8) <.0001
Anxiety 9.8	(4.3) 9.5	(4.8) 5.2	(2.7) .0001
Depression,	median	(IQR) 5.5	(3‐10) 4	(2‐8.8) 1	(1‐2) <.0001
Hospital	Anxiety	and	Depression	Scale 16.3	(7.4) 14.8	(8.2) 6.8	(3.3) <.0001
Perceived	Stress	Scale 19	(7.5) 17.5	(7.9) 11.2	(6.0) .0003
Bowel	frequency,	median	(IQR) 2.6	(1.9‐4) 2.8	(2‐4) 1.1	(1‐1.4) <.0001


















107/125	 IBS‐D	 patients	 completed	 daily	 stool	 diaries	 to	 allow	 as‐
sessment	 of	 response,	 of	 which	 82	 patients	 met	 FDA	 criteria	 for	
stool	form	responders.	As	shown	in	Table	3,	they	had	significantly	
lower	 baseline	 average	 abdominal	 pain	 scores	 and	 pain	 occurred	
on	fewer	days	per	week.	They	also	reported	lower	average	urgency	





3.5 | Features of patients showing increased 
responsiveness to ondansetron (super‐responders)
About	39	IBS‐D	patients	adjusted	their	daily	dose	to	<	4	mg	on‐






depression	 and	 PHQ‐12	 scores	 were	 not	 significantly	 different	
(see	supplementary	data).
There	 were,	 however,	 significant	 differences	 in	 5‐HT	 con‐
centration	 in	 rectal	 biopsies	 which	 were	 significantly	 lower	 in	
super‐responders	 (21.3	 (17.0‐31.8)	vs	37.7,	 (21.4‐61.4),	P	=	 .0357)	
(Figure	2).	There	were	no	differences	between	the	groups	in	biopsy	









































Variable Patients (n = 57)
Healthy volunteers 




biopsy	5‐HIAA/5‐HT 0.06	(0.03‐0.16) 0.02	(0.02‐0.05) .0038
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Table	 5).	 The	 polymorphism	 in	 HTR3E	 c.*76G	 >	 A	 rs561098476	
























(n = 25) P value
Age 40	(12) 45	(11) .0539
Sex	(female),	n	(%) 61	(74) 16	(64) .446
Hospital	Anxiety	and	Depression	Scale 14.7	(7.0) 17.8	(8.3) .0774
Patient	Health	Questionnaire	12 7.4	(3.4) 8.2	(3.9) .3189
Placebo	whole	gut	transit	(hours),	median	(IQR) 18	(9‐31) 10	(6.3‐24.8) .0625
Baseline	days	with	abdominal	pain,	median	(IQR) 5	(3‐7) 7	(5‐7) .0175
Baseline	average	abdominal	pain	score 1.2	(0.7) 1.8	(0.8) .0023
Baseline	days	with	urgency,	median	(IQR) 6	(4.8‐7) 7	(6.5‐7) .0014
Baseline	average	urgency	score,	median	(IQR) 1.4	(1‐2) 2.4	(1.6‐2.6) <.0001
Baseline	days	with	bloating,	median	(IQR) 6	(3‐7) 6	(3.5‐7) .498
Baseline	average	bloating	score 1.3	(0.8) 1.4	(0.9) .4438
Baseline	average	stool	form 5.3	(0.7) 5.5	(0.8) .2498
Baseline	average	stool	frequency,	median	(IQR) 2.6	(1.9‐3.9) 2.9	(1.9‐3.9) .7266
Biopsy	5‐HT	(pmol/mg	protein),	median	(IQR)a 28.6	(18.3‐42) 44.3	(25.5‐65.7) .0642
Biopsy	5‐HIAA	(pmol/mg	protein),	median	(IQR)a 2.1	(1‐4.1) 1.6	(1‐4) .6567
Biopsy	5‐HIAA	/5‐HT,	median	(IQR)a 0.06	(0.03‐0.20) 0.03	(0.02‐0.08) .2731


















































some26 but not all27	studies.	The	current	study	found	significantly	
increased	 mucosal	 concentrations	 of	 the	 5‐HT	 metabolite	 5‐





nists	 has	 been	 confirmed	 in	meta‐analyses3	which	 show	particu‐





dose,	 showed	striking	differences	 in	 the	doses	chosen,	with	over	
half	using	4	mg	or	less	per	day	while	some	used	the	maximum	al‐
lowed	of	24	mg/d.	These	differences	suggest	that	there	existed	a	


















<4 mg  
ondansetron  
(n = 17)
≥4 mg  
ondansetron  
(n = 32) P value







Plasma	5‐HIAA	(nmol/l)a 17	(14.2‐20.0) 16.0	(12.3‐18.1) .1733
Biopsy	TPH1 mRNA relative expressionb 0.61	(0.54‐0.80) 0.61	(0.42‐0.95) .6554
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Having	less	serotonin	in	the	biopsy	could	be	either	because	of	reduced	








portant	 implications.	We	have	previously	 reported	 from	this	 same	
patient	group	that	 the	 faecal	protease	 levels	correlated	negatively	
with	transit	time	and	positively	with	average	urgency	 in	 IBS‐D	pa‐
tients.31	 As	 others	 have	 confirmed,	 urgency	 is	 strongly	 related	 to	


















ondary	 endpoints.	 Since	 our	 study	 was	 carried	 out	 on	 patients	
referred	to	secondary	care	they	can	only	be	generalised	to	this	pop‐













known	SNPs	in	the	genes	encoding	the	SERT	gene	SLC6A4 or TPH1 
with	a	clinically	significant	pattern	of	symptom	features	nor	respon‐
siveness	 to	 ondansetron,	 as	 has	 been	 suggested	 by	 others	 for	 the	
related	drug	ramosetron,34	but	our	numbers	were	probably	too	low	
for	such	an	analysis.	Also	relevant	 is	the	fact	that	we	did	not	find	a	

























(n = 28) P value
Stool	responder	(n	=	22),	% 14 53 33 .0066
Stool	nonresponder	(n	=	73),	% 18 68 14
Average	stool	form,	mean	(SD) 3.6	(1.5) 4.1	(1.3) 3.9	(1) .5143
Average	stool	frequency 2	(1.1‐3.1) 1.8	(1.4‐2.9) 1.6	(1.2‐2.4) .5892
Days	with	abdominal	pain 4	(1.4‐6.5) 6	(2.5‐7) 5	(1.5‐6.5) .0923
Average	abdominal	pain	score 0.6	(0.2‐1.4) 1.4	(0.6‐2.1) 0.9	(0.3‐1.3) .0241
Days	with	urgency 3.8	(2.3‐6.6) 5	(2.4‐6.5) 3	(1‐6.3) .2863
Average	urgency	score,	mean	(SD) 1.2	(1) 1.2	(0.8) 0.8	(0.7) .1276
Days	with	bloating 5	(2‐6.5) 5.8	(1.9‐7) 3	(0.5‐6.3) .207
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Rectal	 biopsy	5‐HT	might	 be	 such	 a	 parameter	 for	 5‐HT	 receptor	
3	antagonists,	however,	rectal	biopsy	assessment	of	5‐HT	turnover	
is	not	currently	a	feasible	clinical	test.	The	 immediate	value	of	our	
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